

## PRODUCT MONOGRAPH

**PrTRISENOX<sup>®</sup>**

**(arsenic trioxide)**

For Injection

10 mg/10 mL (1 mg/mL) ampoule  
12 mg/6 mL (2 mg/mL) stoppered vial

Antineoplastic

Teva Canada Limited  
30 Novopharm Court  
Toronto, Ontario  
M1B 2K9

Date of Preparation:  
January 31, 2018

Date of Revision:  
October 16, 2020

Manufactured for:  
Teva Canada Innovation  
Montréal, Quebec  
H2Z 1S8

Submission Control No: 239659

## **Table of Contents**

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	10
DRUG INTERACTIONS .....	18
DOSAGE AND ADMINISTRATION .....	20
OVERDOSAGE .....	21
ACTION AND CLINICAL PHARMACOLOGY .....	22
STORAGE AND STABILITY.....	24
SPECIAL HANDLING INSTRUCTIONS .....	24
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	25
 <b>PART II: SCIENTIFIC INFORMATION .....</b>	 <b>26</b>
PHARMACEUTICAL INFORMATION.....	26
CLINICAL TRIALS.....	27
DETAILED PHARMACOLOGY .....	29
TOXICOLOGY .....	32
REFERENCES .....	36
 <b>PART III: CONSUMER INFORMATION.....</b>	 <b>41</b>

# Pr**TRISENOX**<sup>®</sup>

Arsenic trioxide

## PART I: HEALTH PROFESSIONAL INFORMATION

### SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Non-medicinal Ingredients
Intravenous infusion	10 mg/10 mL (1 mg/mL) ampoule  12 mg/6 mL (2 mg /mL) stoppered vial	hydrochloric acid to adjust pH, sodium hydroxide, water for injection

### INDICATIONS AND CLINICAL USE

TRISENOX (arsenic trioxide) is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), which is refractory to or has relapsed from retinoid and anthracycline therapy, and whose APL is characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic-acid-receptor alpha (PML-RAR $\alpha$ ) gene expression.

The indication is based on complete response rate. The duration of remission induced by TRISENOX has not been determined.

The response rate of other acute myelogenous leukemia subtypes to TRISENOX has not been examined.

#### **Geriatrics (> 65 years of age):**

There is limited clinical data on the use of TRISENOX in geriatric patients with relapsed or refractory APL. Caution is needed in these patients.

#### **Pediatrics (< 18 years of age):**

Safety and effectiveness in relapsed APL pediatric patients below the age of 5 years have not been studied.

There is limited clinical data on the use of TRISENOX in pediatric patients > 5 years and < 18 years of age with relapsed or refractory APL (see **CLINICAL TRIALS**).

Caution is advised in the use of TRISENOX in pediatric patients. All pediatric patients should be closely monitored for toxicities as the exposure to TRISENOX is expected to be higher than in adult patients (see **ACTION AND CLINICAL PHARMACOLOGY, Special Populations**

**and Conditions**). Dosage adjustments are necessary when administering in obese pediatric patients (see **DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment**).

## **CONTRAINDICATIONS**

TRISENOX is contraindicated in patients who are hypersensitive to arsenic or any of the non-medicinal ingredients in this product. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the product monograph.

TRISENOX is contraindicated during pregnancy and in nursing mothers.

## WARNINGS AND PRECAUTIONS

### Serious Warnings and Precautions

- **APL Differentiation Syndrome**

This syndrome can be fatal. At the first signs or symptoms that could suggest the syndrome, high-dose steroids (dexamethasone 10 mg intravenously BID) should be immediately initiated (see **WARNINGS AND PRECAUTIONS, General**).

- **Acute Cardiac Toxicities (Rhythm Disturbance)**

- Arsenic trioxide can cause QT prolongation and complete atrioventricular block. QT prolongation can lead to torsade de pointes, a polymorphic ventricular tachyarrhythmia, which can be fatal (see **WARNINGS AND PRECAUTIONS, Cardiovascular**).
- Patients with syncope, rapid or irregular heartbeat should be hospitalized for monitoring. Serum electrolytes should be assessed and TRISENOX interrupted (see **DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment**).
- Special electrocardiogram and electrolyte monitoring is required (see **WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests**).
  - Prior to initiating therapy with TRISENOX, a 12-lead electrocardiogram (ECG) should be performed and serum electrolytes (potassium, calcium, and magnesium) and creatinine should be assessed; preexisting electrolyte abnormalities (including hypokalaemia, hypocalcaemia or hypomagnesaemia) should be corrected.
  - For QTc greater than 500 msec, corrective measures should be completed and the QTc reassessed with serial ECGs prior to considering using TRISENOX. TRISENOX therapy may be started at QTc values of less than 430 msec for males, and less than 450 msec for females.
- Concomitant use of drugs that prolong the QT interval or disrupt electrolyte levels should be avoided (see **DRUG INTERACTIONS, Drug-Drug Interactions**).

- Encephalopathy, including fatal outcomes (see **WARNINGS AND PRECAUTIONS, Neurologic**)

- TRISENOX should be administered under the supervision of a physician who is experienced in the management of patients with acute leukemia.

## **General**

### **APL Differentiation Syndrome**

Some patients with APL treated with TRISENOX have experienced symptoms similar to a syndrome called the retinoic acid-APL syndrome or APL differentiation syndrome. Diagnosis of this syndrome should be suspected clinically in the presence of one of the following symptoms and signs: dyspnoea, unexplained fever, weight gain, peripheral oedema, unexplained hypotension, acute renal failure or congestive heart failure and particularly by a chest radiograph demonstrating interstitial pulmonary infiltrates or pleuropericardial effusion with or without leukocytosis. This syndrome can be fatal. The management of the syndrome has not been fully studied, but high-dose steroids have been used at the first suspicion of the APL differentiation syndrome and appear to mitigate signs and symptoms. At the first signs that could suggest the syndrome, high-dose steroids (dexamethasone 10 mg intravenously BID) should be immediately initiated, irrespective of the leukocyte count, and continued for at least 3 days or longer until signs and symptoms have abated. TRISENOX therapy should be temporarily interrupted for patients who develop severe APL differentiation syndrome (see **ADVERSE REACTIONS**).

### **Tumor Lysis Syndrome**

One case of tumor lysis syndrome has been reported in clinical trials in patients treated with TRISENOX.

## **Carcinogenesis and Mutagenesis**

Formal carcinogenicity studies have not been conducted with TRISENOX by intravenous administration. The active ingredient of TRISENOX, arsenic trioxide, is a known human carcinogen (see **DETAILED PHARMACOLGY, TOXICOLOGY**).

Arsenic was either inactive or extremely weak for the induction of gene mutations in vitro. Arsenic tested positive for clastogenicity in vivo and in vitro (see **TOXICOLGY, Genotoxicity**).

## **Cardiovascular**

### **QT Prolongation**

QT prolongation should be expected during treatment with arsenic trioxide. Torsade de pointes and sudden death have been reported.

Torsade de pointes may be asymptomatic or experienced by the patient as dizziness, palpitations, syncope, or seizures. If sustained, torsade de pointes can progress to ventricular fibrillation and sudden cardiac death.

The risk of torsade de pointes is related to the extent of QT prolongation, concomitant administration of QT prolonging drugs or drugs that decrease electrolyte levels. Concomitant use of drugs that prolong the QT interval or disrupt electrolyte levels should be avoided (see **DRUG INTERACTIONS, Drug-Drug Interactions**).

Particular care should be exercised when administering TRISENOX to patients who are suspected to be at an increased risk of experiencing torsade de pointes.

Risk factors for torsade de pointes in the general population include, but are not limited to, the following:

- female gender;
- age 65 years or older;
- baseline prolongation of the QT/QTc interval;
- presence of genetic variants affecting cardiac ion channels or regulatory proteins, especially congenital long QT syndromes;
- family history of sudden cardiac death at <50 years;
- cardiac disease (e.g., myocardial ischemia or infarction, congestive heart failure, left ventricular hypertrophy, cardiomyopathy, conduction system disease);
- history of arrhythmias (especially ventricular arrhythmias, atrial fibrillation, or recent conversion from atrial fibrillation);
- electrolyte disturbances (e.g., hypokalaemia, hypomagnesaemia, hypocalcaemia) or conditions leading to electrolyte disturbances (e.g., eating disorders);
- bradycardia (<50 beats per minute);
- acute neurological events (e.g., intracranial or subarachnoid haemorrhage, stroke, intracranial trauma);
- diabetes mellitus;
- autonomic neuropathy.

TRISENOX should not be administered to patients with QT/QTc interval greater than 500 msec (see **DOSAGE AND ADMINISTRATION**).

**Complete Atrioventricular Block:** Complete atrioventricular block has been reported with arsenic trioxide in the published literature including a case of a patient with APL.

**Increased Heart Rate:** TRISENOX has been reported to increase heart rate. Caution should be observed in patients with conditions that might be exacerbated by an increase in heart rate, such as tachyarrhythmias or ischemic heart disease.

### **Hematologic**

#### **Hyperleukocytosis**

Treatment with TRISENOX has been associated with the development of hyperleukocytosis (white blood cell (WBC)  $\geq 10 \times 10^3/\mu\text{L}$ ) in some patients with relapsed or refractory APL. A relationship did not exist between baseline WBC counts and development of hyperleukocytosis nor baseline WBC counts and peak WBC counts. Hyperleukocytosis was not treated with additional chemotherapy. WBC counts during consolidation were not as high as during induction treatment.

### **Hepatic/Biliary/Pancreatic**

Increases in transaminases have been associated with treatment with TRISENOX. In clinical trials the majority of cases of elevated transaminases resolved without interruption of TRISENOX treatment.

## **Neurologic**

Peripheral neuropathy, characterized by paraesthesia/dysaesthesia, is a common and well known effect of environmental arsenic. Cases of serious and/or irreversible peripheral neuropathy have been observed in patients treated with TRISENOX.

## **Encephalopathy**

Cases of encephalopathy were reported uncommonly with treatment with arsenic trioxide. Wernicke encephalopathy after arsenic trioxide treatment was reported in patients with vitamin B1 deficiency. Patients at risk of B1 deficiency should be closely monitored for signs and symptoms of encephalopathy after arsenic trioxide initiation. Some cases recovered with vitamin B1 supplementation.

## **Sexual Function/Reproduction**

The effect of arsenic on fertility has not been adequately studied in humans. Testicular toxicities, such as decreased testicular weight and impaired spermatogenesis have been reported in animal studies. Arsenic trioxide has been shown to be embryotoxic and teratogenic in animal studies (see **TOXICOLOGY**).

## **Special Populations**

**Pregnant Women:** TRISENOX may cause fetal harm and miscarriage if administered to a pregnant woman. Women should be advised to avoid becoming pregnant throughout treatment and for 3 months after TRISENOX therapy has stopped. Advise patients to report pregnancy immediately.

If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

**Nursing Women:** Arsenic is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from TRISENOX, advise patients to avoid nursing while receiving TRISENOX and for 3 months after TRISENOX therapy has stopped.

**Male patients:** Arsenic may be present in the semen of patients treated with TRISENOX. Men receiving TRISENOX and for 3 months after TRISENOX therapy has stopped should use a condom if the patient is engaged in sexual activity with a pregnant woman or a woman of child-bearing potential.

**Pediatrics (< 18 years of age):** Safety and effectiveness in relapsed APL pediatric patients below the age of 5 years have not been studied.

There is limited clinical data on the use of TRISENOX in pediatric patients > 5 years and < 18 years of age with relapsed or refractory APL (see **CLINICAL TRIALS**).

Obese pediatric patients should be dosed based on ideal body weight (see **DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment**).



**Geriatrics (≥ 65 years age):** There are limited clinical data on the use of TRISENOX in geriatric patients with relapsed or refractory APL. Caution is needed in these patients.

**Patients with Renal Impairment:** Limited data is available across all renal impairment groups. Caution is advised in the use of TRISENOX in patients with renal impairment. All patients with renal impairment should be closely monitored for toxicities. The limited experience in patients with severe renal impairment (creatinine clearance less than 30 mL/min) demonstrates that the exposure of arsenic trioxide may be higher and a dose reduction may be warranted. Renal impairment may result in overdose levels of TRISENOX, which may be fatal if not treated (see **ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Renal Insufficiency**).

The use of TRISENOX in patients on dialysis has not been studied.

**Patients with Hepatic Impairment:** Limited data is available across all hepatic impairment groups. Caution is advised in the use of TRISENOX in patients with hepatic impairment. All patients with hepatic impairment should be closely monitored for toxicities, particularly patients with severe hepatic impairment (Child-Pugh C) which may require a dose reduction (see **ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Hepatic Insufficiency**).

### **Monitoring and Laboratory Tests**

**Electrocardiogram monitoring:** Prior to initiating therapy with TRISENOX, a 12-lead ECG should be performed and serum electrolytes (potassium, calcium, and magnesium) and creatinine should be assessed; preexisting electrolyte abnormalities should be corrected and, if possible, drugs that are known to prolong the QT interval should be discontinued (see **DRUG INTERACTIONS**).

ECGs should be obtained twice weekly, and more frequently for clinically unstable patients, during induction and consolidation. Continuous ECG monitoring should be considered for patients with risk factors for QT prolongation/torsade de pointes.

For QTc greater than 500 msec, corrective measures should be completed and the QTc reassessed with serial ECGs prior to considering using TRISENOX. TRISENOX therapy may be started at QTc values of less than 430 msec for males, and less than 450 msec for females.

**Laboratory parameters monitoring:** The patient's electrolyte (potassium, calcium and magnesium) and glucose levels as well as hematologic, hepatic, renal and coagulation parameter tests should be monitored at least twice weekly, and more frequently for clinically unstable patients during the induction phase and at least weekly during the consolidation phase.

During therapy with TRISENOX, potassium concentrations should be kept above 4 mEq/L and magnesium concentrations should be kept above 1.8 mg/dL.

**Other monitoring:** Obese patients should be closely monitored for signs of serious acute arsenic toxicity (see **DOSAGE AND ADMINISTRATION, Dosing Considerations**).

All patients should be closely monitored for hypoxia and development of pulmonary infiltrates and pleural effusion.

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

The most common adverse events in the multicenter study were nausea, cough, fatigue, pyrexia, headache, vomiting, tachycardia, diarrhoea, and hypokalaemia.

In the multicenter study, leukocytosis occurred in 50% of patients with APL, as determined by hematology assessments. Leukocytosis was recorded as an adverse event in 10% of the patients.

Serious adverse reactions attributed to TRISENOX included APL differentiation syndrome, leukocytosis, prolonged QTc interval  $\geq 500$  msec (including 1 with torsade de pointes), atrial fibrillation/atrial flutter, hyperglycaemia and a variety of serious adverse reactions related to haemorrhage, infections, pain, diarrhoea, nausea. The adverse events leading to dose modifications were chest pain, bacterial infection, upper respiratory tract infection, blood creatinine increased, pain in extremity, hypoaesthesia, paraesthesia, haematuria, and renal failure.

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

Safety information is available for 52 patients with relapsed or refractory APL who participated in two open-label, single-arm, non-comparative studies of TRISENOX. Forty patients in a multicenter study received the recommended dose of 0.15 mg/kg of which 28 completed both induction and consolidation treatment cycles. An additional 12 patients with relapsed or refractory APL received doses generally similar to the recommended dose in a single-center study.

The median number of cumulative doses administered during induction were 34.2 (range, 14 - 60) and 31.5 (range, 5 - 39) in the multicenter and single-center study respectively. The median number of cumulative doses administered during consolidation were 25 (range, 14 - 42) and 25 (range, 25 - 25) in the multicenter and single-center study respectively.

Treatment with TRISENOX has been associated with the development of hyperleukocytosis ( $WBC \geq 10 \times 10^3/uL$ ) in 20 of the 40 patients in the multicenter study.

Nine of 40 patients with APL treated with TRISENOX, experienced symptoms suggestive of the APL differentiation syndrome.

The following table 1 describes the non-hematologic treatment-emergent adverse events (TEAEs) coded in accordance with the MedDRA version 16.0 and National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 1 that were observed in patients treated with TRISENOX at the recommended dose of 0.15 mg/kg/day at a rate of 5% or more in the multicenter study.

**Table 1: Number of Patients with Non-Hematologic Treatment-Emergent Adverse Events (Any Grade) by Body System, Occurring in  $\geq 5\%$  of Patients in Multicenter Study**

System organ class / Adverse Event	Multicenter Study n=40			
	All Adverse Events, Any Grade		Grade 3 and 4	
Number of Patients with Treatment Emergent Adverse Events	n	%	n	%
<b>All Body Systems</b>	<b>40</b>	<b>100</b>	<b>27</b>	<b>68</b>
<b>Cardiac disorders</b>				
Tachycardia	22	55		
Palpitations	4	10		
Arrhythmia	2	5		
Sinus tachycardia	2	5		
<b>Ear and labyrinth disorders</b>				
Ear pain	3	8		
Tinnitus	2	5		
<b>Eye disorders</b>				
Eye irritation	4	10		
Vision blurred	4	10		
Dry eye	3	8		
Eyelid oedema	2	5		
Eye pain	2	5		
<b>Gastrointestinal disorders</b>				
Nausea	30	75		
Diarrhoea	25	63		
Vomiting	23	58		
Abdominal pain	15	38	3	8
Constipation	11	28	1	3
Abdominal pain upper	8	20	1	3
Dyspepsia	4	10		
Mouth haemorrhage	4	10		
Abdominal distension	3	8		
Abdominal tenderness	3	8		
Diarrhoea haemorrhagic	3	8	1	3
Dry mouth	3	8		
Faecal incontinence	3	8		
Gastrointestinal haemorrhage	3	8	1	3
Oral mucosal blistering	3	8		
Flatulence	2	5		
Gingival bleeding	2	5		
Haemorrhoids	2	5		
Lip ulceration	2	5		
Oral pain	2	5		
Proctalgia	2	5		
<b>General disorders and administration site</b>				

System organ class / Adverse Event	Multicenter Study n=40			
	All Adverse Events, Any Grade		Grade 3 and 4	
Number of Patients with Treatment Emergent Adverse Events	n	%	n	%
<b>conditions</b>				
Fatigue	27	68	2	5
Pyrexia	25	63	2	5
Oedema	18	45		
Oedema peripheral	17	43	1	3
Chills	15	38		
Chest pain	10	25	2	5
Injection site pain	9	23		
Pain	7	18	1	3
Injection site erythema	5	13		
Asthenia	4	10	2	5
Crepitations	4	10		
Injection site oedema	4	10		
Face oedema	3	8		
Injection site haemorrhage	3	8	1	3
Injection site reaction	3	8		
Malaise	3	8		
Chest discomfort	2	5		
Discomfort	2	5	1	3
Injection site inflammation	2	5		
Local swelling	2	5	1	3
Mucosal inflammation	2	5		
Swelling	2	5		
<b>Hepatobiliary disorders</b>				
Jaundice	2	5		
<b>Immune system disorders</b>				
Drug hypersensitivity	2	5	1	3
<b>Infections and infestations</b>				
Sinusitis	8	20		
Herpes simplex	5	13		
Upper respiratory tract infection	5	13	1	3
Pneumonia <sup>a</sup>	5	13	2	5
Bacterial infection	3	8	1	3
Herpes zoster	3	8		
Injection site infection	3	8		
Nasopharyngitis	3	8		
Oral candidiasis	2	5		
Sepsis	2	5	2	5
Staphylococcal infection	2	5		
<b>Injury, poisoning and procedural complications</b>				
Procedural pain	5	13	1	3
Laceration	3	8		
<b>Investigations</b>				
Electrocardiogram QT prolonged	13	33	1	3
Blood magnesium decreased	11	28		
Alanine aminotransferase increased	9	23	3	8
Electrocardiogram abnormal	9	23		
Aspartate aminotransferase increased	5	13	1	3
Blood lactate dehydrogenase increased	5	13	2	5

System organ class / Adverse Event	Multicenter Study n=40			
	All Adverse Events, Any Grade		Grade 3 and 4	
Number of Patients with Treatment Emergent Adverse Events	n	%	n	%
Weight increased	5	13		
Breath sounds abnormal	4	10		
Blood alkaline phosphatase increased	3	8	1	3
Blood fibrinogen decreased	3	8	1	3
Blood culture positive	3	8	1	3
Blood urea increased	3	8		
Culture positive	3	8	1	3
Weight decreased	3	8		
Cardiac murmur	2	5		
Cardiac murmur functional	2	5		
Pulse abnormal	2	5		
<b>Metabolism and nutrition disorders</b>				
Hypokalaemia	20	50	5	13
Hyperglycaemia	18	45	5	13
Decreased appetite	15	38		
Hypomagnesaemia	11	28		
Hyperkalaemia	7	18	2	5
Hypocalcaemia	4	10		
Hypoglycaemia	3	8		
Acidosis	2	5	1	3
<b>Musculoskeletal and connective tissue disorders</b>				
Arthralgia	13	33	3	8
Myalgia	10	25	2	5
Bone pain	9	23	4	10
Back pain	7	18	1	3
Neck pain	5	13		
Pain in extremity	5	13	2	5
Pain in jaw	2	5		
<b>Nervous system disorders</b>				
Headache	25	63	1	3
Paraesthesia	13	33	2	5
Dizziness	10	25		
Hypoaesthesia	5	13		
Tremor	5	13		
Convulsion	3	8	2	5
Somnolence	3	8	1	3
Coma	2	5	2	5
Lethargy	2	5	1	3
Neuropathy peripheral	2	5	1	3
<b>Psychiatric disorders</b>				
Insomnia	17	43	1	3
Anxiety	13	33	1	3
Depression	8	20		
Agitation	3	8		
Confusional state	2	5		
Mental status changes	2	5	1	3
<b>Renal and urinary disorders</b>				
Haematuria	5	13		
Renal failure	3	8	1	3

System organ class / Adverse Event	Multicenter Study n=40			
	All Adverse Events, Any Grade		Grade 3 and 4	
Number of Patients with Treatment Emergent Adverse Events	n	%	n	%
Renal impairment	3	8		
Oliguria	2	5		
Proteinuria	2	5		
Urinary incontinence	2	5		
<b>Reproductive system and breast disorders</b>				
Vaginal haemorrhage	5	13		
Metrorrhagia	3	8		
<b>Respiratory, thoracic and mediastinal disorders</b>				
Cough	26	65		
Dyspnoea	16	40	4	10
Oropharyngeal pain	16	40		
Epistaxis	10	25		
Hypoxia	9	23	4	10
Pleural effusion	8	20	1	3
Dyspnoea exertional	6	15		
Upper-airway cough syndrome	5	13		
Wheezing	5	13		
Rales	4	10		
Dysphonia	3	8		
Haemoptysis	3	8	1	3
Rhonchi	3	8		
Tachypnoea	3	8		
Lung infiltration	2	5	1	3
Nasal congestion	2	5		
Pleuritic pain	2	5	2	5
Pneumothorax	2	5		
Productive cough	2	5		
Rhinitis allergic	2	5		
Rhinorrhoea	2	5		
<b>Skin and subcutaneous tissue disorders</b>				
Dermatitis	18	45		
Pruritus	13	33		
Ecchymosis	8	20		
Dry skin	6	15		
Erythema	5	13	1	3
Hyperhidrosis	5	13		
Night sweats	3	8		
Petechiae	3	8		
Skin hyperpigmentation	3	8		
Skin lesion	3	8		
Urticaria	3	8		
Blister	2	5		
Skin exfoliation	2	5		
<b>Vascular disorders</b>				
Hypotension	10	25		
Flushing	4	10		
Hypertension	4	10		
Pallor	4	10		
Haemorrhage	3	8		

<sup>a</sup> Includes 1 patient with lobar pneumonia, 1 patient with pneumonia, 1 patient with pneumonia klebsiella, 1 patient with pneumonia moraxella, 1 patient with pneumonia staphylococcal.

**Electrocardiogram Findings:** Pooled data from 56 patients with evaluable ECG data at steady-state in phase I and II clinical trials show a gradual increase in the QTc interval, reaching a mean  $\pm$  standard deviation (SD) steady-state prolongation of  $47 \pm 5$  msec with a mean  $\pm$  SD half-time of  $6 \pm 2$  days. Twenty-six of these 56 patients (46%) had at least one ECG tracing with a QTc interval greater than 500 msec. Heart rates were elevated by approximately 10 beats per minute relative to baseline in these patients. There are no data on the effect of TRISENOX on the QTc interval during the infusion.

Thirteen of the 40 patients (33%) in the multicenter study reported electrocardiogram QT prolonged as an adverse event and 9 (23%) reported electrocardiogram abnormal as an adverse event. One patient (also receiving amphotericin B) had torsade de pointes during induction therapy for relapsed APL with arsenic trioxide.

**Pediatric Adverse Events:** The following adverse events were reported related to TRISENOX treatment 0.15 mg/kg/day in five pediatric patients (defined as ages 5 through 18; median age 7 years) with relapsed or refractory APL in the pivotal multicenter study: Cardiac disorders (bradycardia), gastrointestinal disorders (diarrhoea haemorrhagic), general disorders and administration site conditions (oedema, pyrexia), investigations (alanine aminotransferase increased, electrocardiogram abnormal, electrocardiogram QT prolonged, heart rate irregular, weight increased), metabolism and nutrition disorders (hyperglycaemia, hypokalaemia), musculoskeletal, connective tissue and bone disorders (arthralgia, joint effusion, myalgia, back pain), nervous system disorders (dizziness, tremor), respiratory, thoracic and mediastinal disorders (dyspnoea, pleural effusion), skin and subcutaneous tissue disorders (petechiae, rash), vascular disorders (flushing). Hypokalaemia (n=1) was considered a serious reaction.

The following additional adverse events were reported as related to TRISENOX treatment 0.15 mg/kg/day in 9 pediatric patients (defined as ages 5 through 18; median age 14 years) with relapsed or refractory APL in a supportive study: gastrointestinal (stomatitis, caecitis), metabolic and nutrition disorders (hyponatraemia, hypoalbuminaemia, hypophosphataemia, and lipase increased), cardiac failure congestive, respiratory (acute respiratory distress syndrome, lung infiltration, pneumonitis, pulmonary oedema, respiratory distress, capillary leak syndrome), neuralgia, and enuresis. Pulmonary oedema (n=1) and caecitis (n=1) were considered serious reactions.

### **Abnormal Hematologic and Clinical Chemistry Findings**

In the multicenter study, the minimum value for each of the hematologic analytes was low, and little improvement was seen during the study. Transient increases in WBC count were observed for those patients who experienced leukocytosis.

Six patients had baseline WBC counts  $>5 \times 10^3/\mu\text{L}$ ; 5 of those patients had increases to greater than  $10 \times 10^3/\mu\text{L}$  during their induction treatment cycle. Fourteen other patients, whose baseline values were  $<5 \times 10^3/\mu\text{L}$ , had increases in WBC count to  $>10 \times 10^3/\mu\text{L}$  during their induction treatment cycle. In this study there did not appear to be a relationship between baseline WBC counts and development of leukocytosis nor did there appear to be correlation between baseline WBC count and peak WBC counts. In all patients in which leukocytosis developed, the WBC

count was either declining or had normalized spontaneously by the time that TRISENOX was stopped at the end of the induction cycle.

The following table 2 describes the hematologic TEAEs that were observed in patients treated with TRISENOX at the recommended dose of 0.15 mg/kg/day at a rate of 5% or more in the multicenter study.

**Table 2: Number of Patients with Hematologic Treatment-Emergent Adverse Events (Any Grade) by Body System, Occurring in  $\geq 5\%$  of Patients in Multicenter Study**

System organ class / Adverse Event	Multicenter Study n=40			
	All Adverse Events, Any Grade		Grade 3 and 4	
Number of Patients with Treatment Emergent Adverse Events	n	%	n	%
<b>Blood and lymphatic system disorders</b>				
Anaemia	8	20	2	5
Thrombocytopenia	7	18	5	13
Febrile neutropenia	5	13	3	8
Leukocytosis	4	10	1	3
Neutropenia	4	10	4	10
Disseminated intravascular coagulation	3	8	3	8
Lymphadenopathy	3	8		

In the multicenter study, most patient's clinical chemistry values were either stable, or, if abnormal they returned to normal by the end of the treatment period.

Adverse events related to electrolyte disturbances were reported in the multicenter study. Hypokalaemia (20, 50%), hypomagnesaemia (11, 28%), hyperkalaemia (7, 18%), hypocalcaemia (4, 10%), acidosis (2, 5%), hypermagnesaemia (1, 3%), and hypophosphataemia (1, 3%) were reported.

Eleven of the 40 patients in the multicenter study had values for aspartate aminotransferase, alanine aminotransferase, bilirubin, or alkaline phosphatase  $>5$  times their baseline levels. No patient had a value meeting the criteria for renal toxicity ( $>4$  times the upper limit of normal serum creatinine).

### **Less Common Clinical Trial Adverse Drug Reactions ( $<5\%$ )**

**Blood and lymphatic system disorders:** Neutrophilia

**Cardiac disorders:** Bradycardia, cardiomyopathy, conduction disorder, pericardial effusion, pericarditis, supraventricular extrasystoles, torsade de pointes, ventricular extrasystoles

**Ear and labyrinth disorders:** Ear haemorrhage, ear discomfort, hearing impaired, mild ear effusion, vestibular disorder



**Eye disorders:** Blepharitis, conjunctival disorder, conjunctival haemorrhage, conjunctivitis, eyelid ptosis, periorbital oedema, photopsia, ocular hyperaemia, retinal haemorrhage

**Gastrointestinal disorders:** Abdominal pain lower, anal ulcer, colitis, dry throat, dysphagia, frequent bowel movements, gastrointestinal pain, gastric ulcer, gingival hypertrophy, haematemesis, ileus, lip dry, oesophagitis, tongue discolouration, tongue disorder

**General disorders and administration site conditions:** Gait disturbance, influenza like illness, injection site induration, injection site thrombosis, mucosal ulceration, mucosal vesicle, tenderness

**Immune system disorders:** Graft versus host disease

**Infections and infestations:** Acute sinusitis, bronchitis, cellulitis, clostridial infection, enterococcal bacteraemia, folliculitis, fungal infection, infection, localised infection, otitis media, pharyngitis, septic shock, staphylococcal sepsis, tonsillitis, tracheitis, urinary tract infection, vaginal infection, viral infection

**Injury, poisoning and procedural complications:** Post procedural haemorrhage, soft tissue injury, transfusion reaction, wound drainage

**Investigations:** Activated partial thromboplastin time prolonged, biopsy bone marrow abnormal, blood chloride increased, blood creatinine increased, blood pressure decreased, blood urea decreased, carbon dioxide decreased, cardiac output decreased, culture throat positive, culture wound positive, haemoglobin decreased, heart rate increased, heart sounds abnormal, occult blood positive, white blood cell count increased

**Metabolism and nutrition disorders:** Diabetes mellitus, hypermagnesaemia, hypophosphataemia, metabolic disorder, polydipsia, tumor lysis syndrome

**Musculoskeletal and connective tissue disorders:** Groin pain, joint effusion, joint stiffness, muscle cramps, muscle twitching, muscle weakness, sensation of heaviness

**Neoplasms benign and malignant and unspecified (including cysts and polyps):** Metastases to meninges, skin papilloma

**Nervous system disorders:** Aphonia, dysgeusia, haemorrhage intracranial, hyporeflexia, intention tremor, myasthenic syndrome, speech disorder, stupor, syncope, tunnel vision

**Psychiatric disorders:** Depressed mood, disorientation, nervousness, restlessness

**Renal and urinary disorders:** Bladder pain, chromaturia, dysuria, nephropathy, pollakiuria

**Reproductive system and breast disorders:** Erectile dysfunction, menopausal symptoms, menorrhagia, vaginal discharge

**Respiratory, thoracic and mediastinal disorders:** Acute respiratory distress syndrome, asthma, atelectasis, bronchospasm, pharyngeal ulceration, pneumonitis, pulmonary alveolar haemorrhage, pulmonary haemorrhage, respiratory distress, sinus congestion, stridor

**Skin and subcutaneous tissue disorders:** Alopecia, decubitus ulcer, exfoliative rash, hyperkeratosis, ingrowing nail, rash erythematous, rash generalised, rash pruritic

**Vascular disorders:** Deep vein thrombosis, jugular vein thrombosis, orthostatic hypotension, vasculitis

### **Post-Market Adverse Drug Reactions**

The following reactions have been reported from world-wide post-marketing surveillance. Because they are reported from a population of unknown size, precise estimates of frequency cannot be made.

**Cardiovascular:** Atrioventricular block, sudden cardiac death, torsade de pointes, ventricular extrasystoles in association with QT prolongation, and ventricular tachycardia in association with QT prolongation

**Nervous system:** peripheral neuropathy, encephalopathy.

**Hematologic disorders:** pancytopenia.

**Respiratory, thoracic, and mediastinal disorders:** A differentiation syndrome, like retinoic acid syndrome, has been reported with the use of TRISENOX for the treatment of malignancies other than APL.

## **DRUG INTERACTIONS**

### **Serious Drug Interactions**

- Concomitant use of drugs that prolong the QT interval or disrupt electrolyte levels should be avoided (see **Drug-Drug Interactions**).

### **Overview**

No drug interactions studies between TRISENOX and other agents have been conducted. However, clinically significant drug-drug interaction cannot be ruled out, based on pharmacokinetic properties of arsenic trioxide.

### **Drug-Drug Interactions**

**QT Prolonging Drugs:** The concomitant use of TRISENOX with another QT prolonging drug should be avoided. Other QT prolonging drugs should be discontinued during TRISENOX treatment, whenever possible. Drugs that have been associated with QT interval prolongation

and/or torsade de pointes include, but are not limited to, the examples in the following list. Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QT prolongation and/or torsade de pointes:

- Class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide);
- Class III antiarrhythmics (e.g., amiodarone, sotalol, ibutilide, dronedarone);
- Class 1C antiarrhythmics (e.g., flecainide, propafenone);
- antipsychotics (e.g., chlorpromazine, pimozide, haloperidol, droperidol, ziprasidone);
- antidepressants (e.g., fluoxetine, citalopram, venlafaxine, amitriptyline, imipramine, maprotiline);
- opioids (e.g., methadone);
- macrolide antibiotics and analogues (e.g., erythromycin, clarithromycin, telithromycin, tacrolimus);
- quinolone antibiotics (e.g., moxifloxacin, levofloxacin, ciprofloxacin);
- antimalarials (e.g., quinine, chloroquine);
- azole antifungals (e.g., ketoconazole, fluconazole, voriconazole);
- domperidone;
- 5-HT<sub>3</sub> receptor antagonists (e.g., dolasetron, ondansetron);
- tyrosine kinase inhibitors (e.g., vandetanib, sunitinib, nilotinib, lapatinib);
- histone deacetylase inhibitors (e.g., vorinostat);
- beta-2 adrenoceptor agonists (e.g., salmeterol, formoterol).

**Drugs that Can Decrease Electrolyte Levels:** The concomitant use of drugs that can disrupt electrolyte levels should be avoided during treatment with TRISENOX. Drugs that can disrupt electrolyte levels include, but not limited to, the following:

- loop, thiazide, and related diuretics;
- laxatives and enemas;
- amphotericin B;
- high dose corticosteroids.

**Anthracyclines:** Previous treatment with anthracyclines may increase the risk of QT prolongation.

The above lists of potentially interacting drugs are not comprehensive. Current information sources should be consulted for newly approved drugs that prolong the QT interval or cause electrolyte disturbances, as well as for older drugs for which these effects have recently been established.

### **Drugs That May Alter Arsenic Concentration**

Multidrug resistance-associated protein (MRP) and P-glycoprotein (gp) were shown to be involved in arsenic efflux in non-clinical studies. Coadministration of drugs that are strong inhibitors of these transporters may reduce the efflux of arsenic and increase tissue concentration of arsenic.

### **Drugs of Which Concentration May Be Altered by Arsenic Trioxide**

In non-clinical studies, arsenic treatment increased cytochrome P450 (CYP)3A4 and CYP2A activity. Indirect evidence from non-clinical studies suggests that CYP2B1/2 activity may also be increased with arsenic treatment (see **DETAILED PHARMACOLOGY**). Arsenic trioxide has the potential to decrease systemic concentration of coadministered drugs that are the substrates of these CYP isoenzymes.

### **Drug-Food Interactions**

Interaction of TRISENOX with food has not been studied in humans. In non-clinical studies, arsenic metabolism was reduced in mice and in rabbits fed with diets low in methionine, choline, or protein, suggesting that poor nutritional status may decrease the capacity to methylate and thereby detoxify arsenic.

### **Drug-Herb Interactions**

Interaction of TRISENOX with herbal products has not been studied.

### **Drug-Laboratory Interactions**

Interaction with laboratory tests have not been established.

### **Drug-Lifestyle Interactions**

No studies on the effects on the ability to drive and operate machinery have been performed.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

TRISENOX should be administered under the supervision of a physician who is experienced in the management of patients with acute leukemia. The special monitoring procedures described in **WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests** should be followed.

Pre-existing electrolyte abnormalities should be corrected prior to initiating therapy with TRISENOX.

TRISENOX should not be administered to patients with baseline QT/QTc interval greater than 500 msec unless corrective measures are completed and the QT/QTc interval is reassessed with serial ECGs.

Dosing of obese patients based on total body weight may result in higher than expected plasma and tissue concentration of arsenical species. Obese patients should be closely monitored for signs of serious acute arsenic toxicity.

Total number of TRISENOX doses should not exceed the maximum number of doses recommended for the induction and consolidation treatments.

## **Recommended Dose and Dosage Adjustment**

TRISENOX is recommended to be given according to the following schedule:

- **Induction Treatment Schedule:** TRISENOX should be administered intravenously at a dose of 0.15 mg/kg daily until bone marrow remission. It should be stopped at any time if substantial toxicity occurs. Total induction dose should not exceed 60 doses.
- **Consolidation Treatment Schedule:** Consolidation treatment should begin 3 to 6 weeks after completion of induction therapy. TRISENOX should be administered intravenously at a dose of 0.15 mg/kg daily for 25 doses over a period up to 5 weeks.

Obese pediatric patients should be dosed based on ideal body weight.

Patients who reach an absolute QT/QTc interval value > 500 msec while on TRISENOX therapy should be reassessed and immediate action should be taken to correct concomitant risk factors. Interruption of TRISENOX therapy should be considered.

During therapy with TRISENOX, potassium concentrations should be kept above 4 mEq/L and magnesium concentrations should be kept above 1.8 mg/dL.

If syncope, rapid or irregular heartbeat develops, the patient should be hospitalized for monitoring and serum electrolytes should be assessed, TRISENOX therapy should be interrupted until the QTc interval regresses to below 460 msec, electrolyte abnormalities are corrected, and the syncope and irregular heartbeat cease.

## **Administration**

### **Ampoules and Vials**

TRISENOX should be diluted with 100 to 250 mL 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, using proper aseptic technique, immediately after withdrawal from the ampoule. TRISENOX ampoule and vial are single-use and do not contain any preservatives. Unused portions of each ampoule or vial should be discarded properly. Do not save any unused portions for later administration.

TRISENOX must not be mixed with or concomitantly administered in the same intravenous line with other medicinal products.

TRISENOX should be administered intravenously over 1-2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. A central venous catheter is not required.

## **OVERDOSAGE**

If symptoms suggestive of serious acute arsenic toxicity (e.g., convulsions, muscle weakness and confusion) appear, TRISENOX should be immediately discontinued and chelation therapy should be considered. A conventional protocol for acute arsenic intoxication includes

dimercaprol administered at a dose of 3 mg/kg intramuscularly every 4 hours until immediate life-threatening toxicity has subsided. Electrocardiogram monitoring is recommended in the event of overdosage.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

Although the mechanism of action of TRISENOX is not completely understood, there is substantial in vitro evidence that its mechanism of action is multimodal and likely depends on dose.

Arsenic trioxide had differential effects in 6 primary APL and in two established APL cell lines (NB4 and MR2). At lower doses (0.1-0.5  $\mu\text{mol/L}$ ), arsenic trioxide promoted partial cellular differentiation, while at higher doses (0.5-5  $\mu\text{mol/L}$ ) it lead to morphological changes and deoxyribonucleic acid (DNA) fragmentation characteristic of apoptosis.

Other key effects of arsenic trioxide include damage or degradation of the fusion protein PML-RAR $\alpha$  and inhibition of growth and angiogenesis (see **DETAILED PHARMACOLOGY**).

### **Pharmacokinetics**

The inorganic, lyophilized form of arsenic trioxide, when placed into solution, immediately forms the hydrolysis product arsenious acid ( $\text{As}^{\text{III}}$ ).  $\text{As}^{\text{III}}$  is the primary pharmacologically active species of arsenic trioxide. Monomethylarsonic acid ( $\text{MMA}^{\text{V}}$ ) and dimethylarsinic acid ( $\text{DMA}^{\text{V}}$ ) are the main pentavalent metabolites formed during metabolism, in addition to arsenic acid ( $\text{As}^{\text{V}}$ ) a product of  $\text{As}^{\text{III}}$  oxidation. Although the trivalent intermediate metabolites ( $\text{MMA}^{\text{III}}$  and  $\text{DMA}^{\text{III}}$ ) were not assayed in the pharmacokinetic studies of TRISENOX, they have been detected as stable metabolites in human urine. The extent to which these trivalent methylated metabolites are clinically relevant is not known; however, non-clinical studies indicate that these metabolic species are active (see **DETAILED PHARMACOLOGY, Pharmacokinetics**).

The pharmacokinetics of arsenical species ( $[\text{As}^{\text{III}}]$ ,  $[\text{As}^{\text{V}}]$ ,  $[\text{MMA}^{\text{V}}]$ ,  $[\text{DMA}^{\text{V}}]$ ) were determined in a limited number of APL or other advanced cancer patients following once daily doses of 0.15 mg/kg for either 5 days per week for 5 weeks or twice weekly for 4 weeks, followed by a 2-week recovery period. Based on the limited pharmacokinetic data available, systemic exposure (AUC) appears to be linear over the total single dose range of 7 to 32 mg (administered as 0.15 mg/kg).

Peak plasma concentrations of  $\text{As}^{\text{III}}$  were reached at the end of infusion (2 hours). Plasma concentration of  $\text{As}^{\text{III}}$  declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase. After administration at 0.15 mg/kg on a daily or twice-weekly regimen, an approximate 2-fold accumulation of  $\text{As}^{\text{III}}$  was observed as compared to a single infusion. The primary pentavalent metabolites,  $\text{MMA}^{\text{V}}$  and  $\text{DMA}^{\text{V}}$ , are slow to appear in plasma (approximately 10-24 hours after first administration of arsenic trioxide), but, due to their longer

half-life, accumulate more upon multiple dosing than does  $\text{As}^{\text{III}}$ . Based on the limited pharmacokinetic data available, the mean estimated terminal elimination half-lives of the metabolites  $\text{MMA}^{\text{V}}$  and  $\text{DMA}^{\text{V}}$  are 32 hours and 70 hours, respectively. The extent of accumulation of these metabolites is dependent on the dosing regimen. Approximate accumulation ranged from 1.4- to 8-fold following multiple dosing as compared to single dose administration.  $\text{As}^{\text{V}}$  is present in plasma only at relatively low levels.

**Distribution:** The volume of distribution ( $V_{\text{ss}}$ ) for  $\text{As}^{\text{III}}$  is large ( $> 400 \text{ L}$ ) indicating that  $\text{As}^{\text{III}}$  is widely distributed throughout body tissues with negligible protein binding. Although  $V_{\text{ss}}$  is dependent on body weight and increases as body weight increases, this correlation might not hold true in obese patients as there is no evidence that the arsenical species distribute in adipose tissues. Total arsenic accumulates mainly in the liver, kidney, and heart and, to a lesser extent in the lung, hair, and nails.

**Metabolism:** The metabolism of arsenic trioxide involves methylation to the less cytotoxic metabolites,  $\text{MMA}^{\text{V}}$  and  $\text{DMA}^{\text{V}}$  by methyltransferases, primarily in the liver. The metabolism of arsenic trioxide also involves oxidation of  $\text{As}^{\text{III}}$  to  $\text{As}^{\text{V}}$ , which may occur in numerous tissues via enzymatic or nonenzymatic processes.  $\text{As}^{\text{V}}$  is present in plasma only at relatively low levels following administration of arsenic trioxide.

**Excretion:** Approximately 15% of the administered TRISENOX dose is excreted in the urine as unchanged  $\text{As}^{\text{III}}$ . The remainder is primarily excreted in the urine as the methylated metabolites of  $\text{As}^{\text{III}}$  (10-20% as  $\text{MMA}^{\text{V}}$ , 60-70% as  $\text{DMA}^{\text{V}}$ ). The total clearance of  $\text{As}^{\text{III}}$  is 49 L/h and the renal clearance is 9 L/h. A 45% reduction in total clearance of  $\text{As}^{\text{III}}$  is observed upon multiple dosing. The observed reduction in total clearance might contribute to the accumulation of  $\text{As}^{\text{III}}$ . Clearance is not dependent on body weight or dose administered over the range of 7-32 mg.

### **Special Populations and Conditions**

**Pediatrics:** Although there is limited data on the use of TRISENOX in pediatric patients with relapsed or refractory APL, exposure in pediatric patients is expected to be  $> 50\%$  higher than that in adults (see **WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics**).

**Geriatrics:** The effect of age on the pharmacokinetics of TRISENOX has not been studied (see **WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics**).

**Gender:** The effect of gender on the pharmacokinetics of TRISENOX has not been studied.

**Race:** The effect of race on the pharmacokinetics of TRISENOX has not been studied.

**Hepatic Insufficiency:** The effect of hepatic impairment on the pharmacokinetics of  $\text{As}^{\text{III}}$ ,  $\text{As}^{\text{V}}$ , and the pentavalent metabolites  $\text{MMA}^{\text{V}}$  and  $\text{DMA}^{\text{V}}$  was evaluated following administration of 0.25-0.50 mg/kg of arsenic trioxide in patients with hepatocellular carcinoma. Patients were classified as having normal hepatic function ( $n=4$ ), mild hepatic impairment (Child-Pugh A,  $n=12$ ), moderate hepatic impairment (Child-Pugh B,  $n=3$ ), or severe hepatic impairment (Child-Pugh C,  $n=1$ ). These limited data demonstrated no clear trend toward an increase in systemic exposure to  $\text{As}^{\text{III}}$ ,  $\text{As}^{\text{V}}$ ,  $\text{MMA}^{\text{V}}$  or  $\text{DMA}^{\text{V}}$  with decreasing level of hepatic function as assessed by dose-normalized (per mg dose) area-under-the-curve (AUC) in the mild and moderate hepatic

impairment groups. There is insufficient data for patients with severe hepatic impairment. These patients should be closely monitored for toxicity (see **WARNINGS AND PRECAUTIONS, Special Populations, Hepatic Impairment**).

**Renal Insufficiency:** The effect of renal impairment on the pharmacokinetics of As<sup>III</sup>, As<sup>V</sup> and the pentavalent metabolites MMA<sup>V</sup> and DMA<sup>V</sup> was evaluated in 20 patients with advanced malignancies. Patients were classified as having normal renal function (creatinine clearance [CrCl] > 80 mL/min, n=6), mild renal impairment (CrCl 50-80 mL/min, n=5), moderate renal impairment (CrCl 30-49 mL/min, n=6), or severe renal impairment (CrCl < 30 mL/min, n=3). Following twice weekly administration of 0.15 mg/kg over a 2-hour infusion, the mean AUC<sub>0-∞</sub> for As<sup>III</sup> was comparable among the normal, mild and moderate renal impairment groups.

In the severe renal impairment group, the mean AUC<sub>0-∞</sub> for As<sup>III</sup> was approximately 48% higher and the plasma clearance was 40% lower when compared with patients with normal renal function.

Systemic exposure to MMA<sup>V</sup> and DMA<sup>V</sup> tended to be larger in patients with renal impairment; however, the clinical consequences of this increased exposure are not known. As<sup>V</sup> plasma levels were generally below the limit of assay quantitation in patients with impaired renal function (see **WARNINGS AND PRECAUTIONS, Special Populations, Renal Impairment**).

The use of arsenic trioxide in patients on dialysis has not been studied.

**Genetic Polymorphism:** The effect of genetic polymorphisms on the pharmacokinetics of TRISENOX has not been studied.

## STORAGE AND STABILITY

Store at controlled room temperature (15 to 30°C). Do not freeze.

### Ampoule and Vial

After dilution in 5% Dextrose or 0.9% Sodium chloride, TRISENOX is chemically and physically stable when stored for 24 hours at room temperature and 72 hours when refrigerated.

For single use only. Unused portions of each ampoule or vial must be discarded properly. Do not save any unused portions for later administration.

## SPECIAL HANDLING INSTRUCTIONS

Use caution during handling and preparation. Use of gloves and safety glasses is recommended to avoid exposure.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.



## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

### **Ampoule**

TRISENOX contains 1 mg/mL arsenic trioxide. Non-medicinal ingredients: hydrochloric acid (used to adjust pH), sodium hydroxide, and water for injection.

TRISENOX is supplied as a sterile, clear, colourless solution in 10 mL glass, single-use ampoules in packages of 10 ampoules.

### **Vial**

TRISENOX contains 2 mg/mL arsenic trioxide. Non-medicinal ingredients: hydrochloric acid (used to adjust pH), sodium hydroxide, and water for injection.

TRISENOX is supplied as a sterile, clear, colourless solution in 6 mL glass, single-use vials in packages of 10 vials.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: Arsenic trioxide


Chemical name: Arsenous Acid, Arsenous Acid Anhydride, Arsenic Oxide, Arsenic Sesquioxide, White Arsenic

Molecular formula and molecular mass:  $\text{As}_2\text{O}_3$  197.8 g/mol

Structural formula:



cubic



monoclinic

Physicochemical properties: Arsenic trioxide is a white or transparent, glassy, crystalline powder; sparingly and extremely slowly soluble in cold water; soluble in 15 parts boiling water, in diluted HCl, in alkali hydroxide or carbonate solutions; practically insoluble in alcohol, chloroform, ether.

## CLINICAL TRIALS

TRISENOX has been investigated in 52 relapsed or refractory APL patients, previously treated with an anthracycline and a retinoid regimen, in two open-label, single-arm, non-comparative studies. One pivotal multicenter study was conducted in 40 patients with relapsed or refractory APL. The results from the pivotal study are supported with data from a single-center study in 12 patients. Patients in the multicenter study received a fixed dose of 0.15 mg/kg/day and patients in the single-center study received a median dose of 0.16 mg/kg/day of TRISENOX (range 0.06 to 0.20 mg/kg/day; 2 patients received 0.15 mg/kg/dose). Treatment was administered daily during induction until bone marrow remission was achieved or a maximum of 60 doses were administered (whichever occurred earlier). Patients with complete remission (CR) received consolidation therapy with TRISENOX for 25 additional doses over a 5 week period. Consolidation therapy began 4 weeks (range: 3 – 6) after induction in the multicenter study and 6 weeks (range: 3 – 8) after induction in the single-center study.

### Study Demographics and Trial Design

**Table 3: Summary of patient demographics for clinical trials in APL**

<b>Trial design</b>	<b>Dosage, route of administration and duration</b>	<b>Study subjects (n=number)</b>	<b>Mean age (Range)</b>	<b>Gender</b>
Multicenter, open-label, single-arm pivotal study	Arsenic trioxide infused i.v. for 1 to 4 hours daily, 0.15 mg/kg to CR or maximum 60 days for induction and up to 25 days for consolidation	n=40	40 years (5 – 73 years)	40% male 60% female
Single-center, open-label, single-arm study	Arsenic trioxide infused i.v. daily, 5, 10, 15 mg or 0.15 mg/kg to CR or maximum 60 days for induction and 25 days for consolidation	n=12	38 years (9 – 75 years)	67% male 33% female

CR=complete remission; i.v.=intravenous

In the multicenter study, of the 40 patients enrolled, 16 were male and 24 were female. The mean age was 39.6 years (range: 5 to 73 years). Five pediatric patients (age < 18 years) were enrolled. Of the enrolled patients, 30 were Caucasian, 5 were black, 3 were Hispanic, and 2 were Pacific Islanders. The number of months since initial diagnosis ranged from 9 to 53.8 (mean 22.7, median 18.1). Nineteen patients had undergone 1 prior treatment regimen prior to enrolment, 17 patients had 2 prior regimens, 3 patients had 3 prior regimens, and 1 had 4 prior regimens. Five patients had bone marrow transplantation (BMT) prior to enrolment.

In the single-center study, of the 12 patients enrolled, 8 were male and 4 were female. The mean age was 38 years (range 9 to 75 years). Two pediatric patients were enrolled. Nine patients were

Caucasian and 3 were black. The number of months since initial diagnosis ranged from 11.9 to 61.6 (mean 26.2 and median 21.1). Three patients had undergone 1 prior treatment regimen prior to enrolment, 3 had 2 prior regimens (1 had prior BMT also), and 6 had  $\geq 3$  prior regimens (1 had 6 prior regimens + BMT). The minimum number of doses administered was 5 and the maximum was 64.

The primary efficacy endpoint in both the studies was the incidence of CR after arsenic trioxide therapy. CR was defined as cellular bone marrow aspirate with  $< 5\%$  blasts, peripheral blood leukocyte count  $\geq 3,000/\text{mm}^3$  or absolute neutrophil count  $\geq 1,500/\text{mm}^3$ , and platelet count  $\geq 100,000/\text{mm}^3$ . Complete remission was considered to have occurred on the date on which the last of the criteria was met. In addition to the conventional criteria for disease response described above, assessment of molecular markers for APL was performed using Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) analysis for PML-RAR $\alpha$  gene expression which is unique to this disease. Cytogenetic analysis of bone marrow cells was also performed.

### Study Results

Thirty-four of 40 patients (85%) in the multicenter study and 11 of 12 patients (92%) in the single-center study achieved CR. Overall, 45 of 52 patients (87%) achieved CR.

In the multicenter study, the median time to complete response was 59 days. The duration of follow-up ranged from 280 to 791 days.

The efficacy results of both studies are summarized in the Table 4 below.

**Table 4: Results of Single-center and Multicenter Studies**

	<b>Single-center Study N = 12</b>	<b>Multicenter Study N = 40</b>
<b>Arsenic trioxide Dose, mg/kg/day (median, range)</b>	0.16 (0.06-0.20)	0.15
<b>CR</b>	11 (92%)	34 (85%)
<b>Time to CR (median)</b>	54 days	59 days

CR=complete remission

Of 7 patients with relapsed or refractory APL below the age of 18 years treated with TRISENOX, at the recommended dose of 0.15 mg/kg/day, 5 achieved CR. The multicenter trial included 5 pediatric patients ( $<18$  years old), 3 of whom achieved CR. The single-center study included 2 pediatric patients ( $<18$  years old), both of whom achieved CR. No children of less than 5 years of age were treated in the two studies.

In the multicenter study, cytogenetic confirmation of conversion to a normal genotype was observed in 31 of the 34 (91%) patients in CR, most often by molecular confirmation as well as classical cytogenetics. RT-PCR conversions to normal were documented in 26 of 34 (76%) of the CRs. Cytogenetic confirmation of conversion to a normal genotype and RT-PCR detection of

PML-RAR $\alpha$  conversion to normal for both studies are shown in the Table 5 below.

**Table 5: Cytogenetics after TRISENOX therapy**

	Single-center Study Number with CR = 11	Multicenter Study Number with CR = 34
<b>Conventional cytogenetics</b> [t(15;17)]		
Absent	8 (73%)	31 (91%)
Present	1 (9%)	1 (3%)
Not evaluable	2 (18%)	2 (6%)
<b>RT-PCR for PML-RAR<math>\alpha</math></b>		
Negative	8 (73%)	26 (76%)
Positive	3 (27%)	5 (15%)
Not evaluable	0	3 (9%)

CR=complete remission

Responses were seen across all age groups tested, ranging from 6 to 75 years. The response rate was similar for both genders. There were insufficient patients of Black, Hispanic or Asian derivation to estimate relative response rates in these groups, but responses were seen in members of each group. There is no experience on the effect of TRISENOX on the variant APL containing the t(11;17) and t(5;17) chromosomal translocations.

## DETAILED PHARMACOLOGY

### Pharmacodynamics

The mechanism of action of arsenic trioxide is not completely understood. Studies using the NB4 cell line (a leukemic cell line derived from APL patients) showed morphological changes and DNA fragmentation characteristic of apoptosis after exposure to arsenic trioxide at the same concentration achieved in APL patients in clinical studies in China (0.5 to 2.0  $\mu$ M). The mechanism by which arsenic trioxide induces apoptosis in APL cells partly involves the relocation and degradation of the PML-RAR $\alpha$  fusion protein.

In addition, the ability of arsenic trioxide to induce apoptosis in leukemic cells is thought to depend on the activity of enzymes that regulate cellular hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) content. Abnormally high levels of intracellular H<sub>2</sub>O<sub>2</sub> are thought to lead to apoptosis through the pathway of mitochondrial membrane degradation, cytochrome c, release, caspase activation, and DNA fragmentation. Levels of the peroxidase-catabolizing enzymes glutathione (GSH)-peroxidase and catalase were found to be low, and H<sub>2</sub>O<sub>2</sub> levels high, in NB4 cells relative to other cell lines that are less sensitive to the apoptotic effects of arsenic. When these enzymes were inhibited in U937 leukemic cells, they became more sensitive to the apoptotic effects of arsenic trioxide, suggesting that high H<sub>2</sub>O<sub>2</sub> concentration is the key leading to the apoptotic pathway mentioned above.

Arsenic affects numerous intracellular signal transduction pathways and causes many alterations in cellular function. These actions of arsenic may result in the induction of apoptosis, the

inhibition of growth and angiogenesis, and the promotion of differentiation. These effects have been observed in cultured cell lines and animal models, as well as clinical studies. The trivalent form of arsenic disrupts the thiol groups of many regulatory proteins. The pyruvate dehydrogenase system is particularly sensitive to this reaction.

Apoptosis in leukemic cells is regulated by the intracellular redox equilibrium. The specific target in t(15;17)-dependent APL cells is the chimeric PML-RAR $\alpha$  protein, believed to be central to most APLs. By changing the phosphorylation status of the PML component of the protein, arsenic trioxide promotes the relocation of the PML-RAR $\alpha$  to mature nuclear bodies, initiating proteasome-dependent degradation.

The early mortality of patients with APL treated with standard chemotherapeutic agents is frequently related to severe coagulopathy leading to hemorrhaging, particularly in the brain. In vitro studies suggest that arsenic trioxide and all-*trans*-retinoic acid (ATRA) may affect APL coagulopathy by reducing procoagulant activity and tissue factor gene expression.

The effects of arsenic trioxide in an in vivo murine model mirror those seen in treatment of APL in humans. Nude mice injected intraperitoneally (ip) with leukemic cells from PML-RAR $\alpha$  transgenic mice expressing features of APL survived for an average of 61 days. Recipient mice treated with arsenic trioxide (5.0 mg/kg ip) survived for an average of 76 days. Survival of recipient mice given both arsenic trioxide and ATRA was increased approximately 2-fold (105 days) compared to either treatment alone, suggesting that the mechanisms by which these 2 drugs affect leukemic cells may be complementary yet independent of one another. Survival of untreated PML-RAR $\alpha$  transgenic mice was limited (9 days) and similarly extended by arsenic trioxide treatment (2.5 mg/kg) alone (37 days) or in combination with ATRA (72 days).

In an ATRA-resistant APL in vivo model, generated by subcutaneous (sc) inoculation of the RA-resistant UF-1 cell line into human granulocyte-macrophage colony stimulating factor (GM-CSF)-producing transgenic severe combined immune-deficient (SCID) mice, arsenic trioxide (9.43 mg/kg sc) administered daily for 21 days decreased the tumor volume by approximately 50% at 21 days relative to either vehicle-treated or ATRA-treated mice. Arsenic trioxide also reduced the volume of UF-1 tumor xenografts transplanted into non-obese diabetic (NOD)/SCID mice. The mechanism leading to decreased tumor volume as studied in vitro however appeared to differ between the 2 systems with arsenic trioxide inducing differentiation in the presence of GM-CSF and apoptosis in its absence.

Arsenic trioxide enhances the sensitivity of neoplastic cell lines and tumor xenografts to radiation therapy. In vivo, this activity of arsenic trioxide has been related to its antivasculogenetic activity as it can decrease blood flow in tumour xenografts.

### **Pharmacokinetics**

Arsenic distributes rapidly to highly perfused organs and tissues (e.g., liver, kidney, lung, spleen) in animal models. Three to 30 days postdose, the highest arsenic concentrations are found in the skin, hair, upper gastrointestinal tract, epididymis, lens of the eye, and thyroid. Arsenic crosses the blood-brain barrier in animal models.

Methylation is the principal route of metabolism of arsenite salts in different species. Both

methyated trivalent ( $\text{MMA}^{\text{III}}$  and  $\text{DMA}^{\text{III}}$ ) and pentavalent ( $\text{MMA}^{\text{V}}$  and  $\text{DMA}^{\text{V}}$ ) metabolites were detected in vivo. In non-clinical studies,  $\text{MMA}^{\text{III}}$  and  $\text{MMA}^{\text{V}}$  are more toxic than  $\text{As}^{\text{III}}$  and trivalent arsenicals are more toxic than analogous pentavalent compounds, whereas  $\text{DMA}^{\text{V}}$  has relatively little toxicity. The methyated metabolites of inorganic arsenic (ie,  $\text{MMA}^{\text{V}}$ ,  $\text{DMA}^{\text{V}}$ ), but not arsenic trioxide, have been found to induce mitotic arrest in Chinese hamster V79 cells. The methyated metabolites of arsenic trioxide may be carcinogenic following long-term exposure.  $\text{DMA}^{\text{V}}$  was also found to induce aneuploidy in mouse bone marrow cells after intraperitoneal administration of 300 mg/kg.

Arsenic metabolism was reduced in mice and in rabbits fed diets low in methionine, choline, or protein, suggesting that poor nutritional status may decrease the capacity to methylate and thereby detoxify arsenic. Studies in animals showed that reagents that inhibit the methylation enzymes (e.g. periodate-oxidized adenosine) caused an increase in tissue levels of inorganic arsenic. Similarly, cellular GSH levels appear to play a role in the methylation process, and treatment with reagents (e.g. phorone) that decrease GSH levels increases arsenic toxicity.

Both *cyp2A4* and *cyp2A5* mRNA levels and CYP2A enzyme activity were significantly elevated in the livers of ICR mice after 10 days of treatment with sodium arsenite. Treatment with the compound also increased mRNA, protein and CYP3A4 activity in small intestine of CYP3A4 transgenic mice in a dose-dependent manner. However, in each case, the increase in protein expression was not as marked as compared to the increase in mRNA levels. Hexobarbitone sleeping times were reduced in rats at arsenic doses of 500 ppm (approximately half the daily recommended human dose) and above, suggesting that liver enzyme activity (e.g. CYP2B1 and CYP2B2) was increased.

Arsenic(+3)methyltransferase (*AS3MT*) catalyzes the methylation of arsenite to monomethylarsonic acid (MMA) and from MMA to dimethylarsinic acid (DMA).

Studies in animals showed that reagents that inhibit the methylation enzymes (e.g. periodate-oxidized adenosine) caused an increase in tissue levels of inorganic arsenic. Similarly, cellular GSH levels appear to play a role in the methylation process, and treatment with reagents (e.g. phorone) that decrease GSH levels increases arsenic concentration and toxicity.

### **Cardiovascular Safety Pharmacology**

In a parallel group, vehicle-controlled study in urethane-anaesthetized guinea pigs (N=6-8/treatment), arsenic trioxide (0.15 mg/kg, 0.45 mg/kg, and 1.5 mg/kg infused intravenously over 2 h) had little or no effect on heart rate, but caused a statistically significant and dose-dependent prolongation of the QT/QTc interval, which increased progressively over the 2 h infusion period. After the 2 h infusion, the guinea pigs were sacrificed and the papillary muscles were excised. The action potential duration at 90% of repolarization showed a statistically significant and dose-dependent prolongation in the animals that had received 0.15 mg/kg, 0.45 mg/kg, and 1.5 mg/kg arsenic trioxide, which was more pronounced at low stimulation frequencies.

HERG- or KCNQ1+KCNE1-transfected CHO cells were analyzed for effects of arsenic trioxide on repolarizing cardiac ion currents. Arsenic trioxide caused concentration-dependent block of both  $I_{\text{Kr}}$  and  $I_{\text{Ks}}$ . Arsenic trioxide also activated a time-independent current that additional experiments identified as  $I_{\text{K-ATP}}$ .

In isolated guinea pig ventricular myocytes, overnight exposure to extracellularly applied arsenic trioxide at 3  $\mu\text{M}$  significantly increased action potential duration at 30% and 90% of repolarization, increased calcium currents, and decreased  $I_{Kf}$  potassium currents. Overnight exposure to arsenic trioxide caused a concentration-dependent reduction of the surface expression of hERG channels in HEK293 cells stably transfected with the hERG gene with an  $\text{IC}_{50}$  of 1.5  $\mu\text{M}$ .

## **TOXICOLOGY**

The toxicity of arsenicals in animals depends on the species, sex, age, dose, and duration of exposure. Arsenic interferes with the action of enzymes, essential cations, and transcriptional events in cells throughout the body, and high-dose exposure induces a multitude of systemic effects. Renal and hepatic effects were observed in mice, rats, dogs and adolescent monkeys; nervous system and hematologic effects were found in rats; and hematologic effects were seen in dogs.

### **Acute Toxicity**

The acute lethality of arsenic trioxide has been evaluated in mice. The median lethal dose ( $\text{LD}_{50}$ ) values were 10.7, 9.8 to 12.3, 11.0 to 11.8, and 25.8 to 47.6 mg/kg when arsenic trioxide was given to mice by the intravenous, subcutaneous, intraperitoneal, and oral routes, respectively.

### **Repeat-dose Toxicity**

The repeat-dose toxicity of arsenic trioxide and trivalent arsenic has been studied through a variety of routes of administration including oral, intraperitoneal and intravenous in mice, rats, dogs and monkeys.

The effects of arsenic trioxide in beagle dogs following intravenous infusions for 90 days, followed by a 28-day observation period were evaluated. Ten male and 10 female beagle dogs were divided into 1 control group and 4 treatment groups, 2 dogs/sex/group. Arsenic trioxide was administered by intravenous infusion at up to 3.0 mg/kg/day. Doses were administered once daily for 6 consecutive days each week, with no treatment on the seventh day. Half of the animals were maintained for a 28-day observation period following cessation of dosing. The study showed that repeated administration of high doses of arsenic trioxide over a 90-day period results in arsenic accumulation in tissues, toxic effects in the liver (decreased cytoplasmic density, mis-shaped nuclei, nucleolus absent) at the 1.0 and 3.0 mg/kg/day dose, kidney (decreased size of glomera and glomeruli, decreased number of blood vessels, decreased or enlarged renal pelvis, with necrotic and inflamed cells in the expanded renal pelvis) at the 3.0 mg/kg/day dose, and hematologic effects on red blood cells (decreased red blood cells and hemoglobin levels, and increased mean corpuscular volume) at the 3.0 mg/kg/day dose. Most of these effects subside after cessation of treatment. No signs of local irritation by arsenic trioxide were observed in the injection sites of any animals. No significant toxic effects were observed at dosages of 0.1 and 0.3 mg/kg/day. No abnormalities were observed in all tissues in all animals at the 0.3 mg/kg/day dose.



Nervous system, hematologic, renal, and hepatic effects were seen in rats receiving up to 13.8 mg/kg/day sodium arsenite in diet for up to 2 years. Dogs receiving sodium arsenite in the diet for up to 2 years had increased mortality and hepatic changes at 3.125 mg/kg/day (high dose).

### **Genotoxicity**

Studies of the mutagenic potential of arsenic were conducted in 4 in vitro assays: Ames assay, a mouse lymphoma test, a Chinese V79 transformed cell line, and a Syrian hamster embryo cell assay. Arsenic was either inactive or extremely weak for the induction of gene mutations in the in vitro assays. The Ames assay was negative. Co-mutagenicity with N-methyl-N-nitrosurea as a result of inhibition of DNA repair by arsenic in a transformed Chinese hamster V79 cell line was demonstrated. Induction of sister chromatid exchanges and chromosomal aberrations by arsenic were seen in Syrian hamster embryo cells and human peripheral lymphocytes. The concentration that induced chromatid aberrations was 259.8 ng/mL. Based on a mean  $C_{max}$  from clinical trials of 24.3-37.7 ng-Eq/mL, the safety margin would be approximately 6.9-10.7 fold. In vivo, the clastogenic effects of sodium arsenite were confirmed in a mouse micronucleus assay. Arsenite produced dose-related linear increases in micronuclei in mouse bone marrow at a dose range of 0.5-10 mg/kg. The clastogenic effects in somatic cells did not appear to extend to inheritable effects in germ cells in a mouse dominant lethality assay.

Studies of the potential mechanisms for genotoxicity indicated that arsenic has the potential to interfere with DNA repair by inhibiting DNA ligase activity, amplifying gene expression, and inducing either hyper- or hypo-methylation of DNA.

On the basis of the genotoxicity profile, chromosomal alterations rather than point mutations are more likely to be involved in the observations of arsenic-related genotoxicity in vitro and carcinogenicity in humans.

### **Carcinogenicity**

Epidemiological data indicate that arsenic causes cancer of the skin, bladder, kidney, liver, prostate and lung in humans. This correlates with accumulating evidence for the induction of malignant lymphomas/leukemia and carcinogenicity (including preneoplastic changes) of the skin, bladder, lung, liver, kidney, testis, uterus, bone, and eye by arsenic in numerous animal models (mouse, rat and hamster) that were administered arsenic through feed and water. However, limited evidence for its carcinogenic potential has been demonstrated via the clinically relevant route of intravenous administration by Waalkes et al (2000). Once a week intravenous injections of sodium arsenate (0.5 mg/kg) into Swiss mice for 20 weeks and monitored up to 96 weeks lead to preneoplastic lesions in uterus and testis, and in the female liver. Assuming a mean body weight in the mouse of 35 grams, the dose evaluated by Waalkes et al (2000) is equivalent to 0.018 mg sodium arsenate/week or 0.0025 mg/day. Presented as arsenic equivalents, this corresponds to a daily dose of 0.001 mg-eq/day. By comparison, the labeled dose of arsenic trioxide is 0.15 mg/kg/day, which is equivalent to a 4.0 mg-eq/day in a 70 kg human. The quantitative dose-response data from some animal studies is not considered to be reliable for determining levels of significant human exposure.

## **Reproductive and Developmental Toxicity**

Reproductive toxicity studies of arsenic trioxide using parenteral routes of administration have been conducted in mice, rats, and hamsters. Most of the studies used inorganic forms of arsenic, chiefly the sodium salts of arsenite and arsenate.

Arsenic is known to cross the placental barrier. Animal data indicate that arsenic has the potential to cause developmental toxicity, including malformations, in a variety of species at maternally toxic doses. When sodium arsenite was given to pregnant hamsters by intraperitoneal injection at doses of 2.5 mg/kg (days 9 or 10) and 5 mg/kg (days 8, 11, or 12) fetal growth was decreased with the day 11 and day 12 treatment at 5 mg/kg. Fetal deaths were increased significantly with 5 mg/kg dosing on days 8 and 11. Gross malformations (micromelia, syndactyly, micrognathia, encephalocele, facial malformations and twisted hind limb) were observed in fetuses exposed to arsenic on days 8 or 9. Skeletal malformations (fused ribs) were seen with treatment on days 8 or 10.

Sodium arsenite given as a single intraperitoneal injection to pregnant mice at a maternally lethal dose (12 mg/kg) during organogenesis resulted in fetal malformations (exencephalies, open eyes and fused ribs) and prenatal deaths, without affecting fetal weight. Intraperitoneal administration of arsenic trioxide to pregnant rats on gestational day 9 at doses of 1, 5, 10, or 15 mg/kg or sodium arsenate at 5, 10, 20 and 35 mg/kg resulted in maternal toxicity including mortality at 10 and 15 mg/kg arsenic trioxide and decreased body weight and food consumption at 20 and 35 mg/kg sodium arsenate. Increased resorptions, decreased viable litter sizes and decreased fetal weight was seen in dams given 10 mg/kg arsenic trioxide. The intraperitoneal administration of 10 mg/kg arsenic trioxide and 10 and 35 mg/kg of sodium arsenate increased the incidence of fetal malformations (exencephaly, microphthalmia/anophthalmia and other craniofacial defects). Intraperitoneal injection of 1 or 5 mg/kg arsenic trioxide on gestation day 9 did not produce any maternal toxicity and did not adversely affect intrauterine parameters.

A series of studies were completed that resulted in the development of a mouse model where inorganic arsenic acts as a complete transplacental carcinogen. Brief exposure in utero to arsenic in drinking water resulted in the formation of a variety of malignant, benign and preneoplastic lesions in the liver, lung, bladder, adrenal, kidney, ovaries, uterus, oviduct and vagina in the offspring after they reached adulthood. It is hypothesized that fetal arsenic exposure may induce aberrant genetic programming as part of its genotoxic reprogramming.

Testicular toxicities including impaired spermatogenesis were found in male animals treated with intravenous or oral arsenic compounds. In beagle dogs following intravenous arsenic trioxide infusion for 90 days, reduced inner cell layers within seminiferous tubules, significantly decreased number of spermatocytes, spermatozoa and sperm cells were observed at doses of 1.0 mg/kg/day and higher. Male mice sacrificed following 35 days of treatment (7.5 mg/kg in drinking water) showed decreased sperm motility, increased abnormal sperm morphology, and decreased sperm viability. In a parallel group, mice with same sodium arsenate exposure were allowed to recover for 35 days after the last day of treatment. At the end of recovery period, sperm motility had recovered but increased abnormal sperm morphology was still apparent. In a rat study, sodium arsenate treatment (5 mg/kg via drinking water for 4 weeks) resulted in decreased testicular weights, epididymal sperm count, plasma follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone and testicular testosterone concentrations, and

germ cell degeneration. Administration of human chorionic gonadotropin along with sodium arsenate partially prevented the germ cell degeneration and maintained testicular weights and epididymal sperm counts.

### **Local Tolerance**

The local tolerance to intravenous injections of arsenic trioxide was studied in a repeated-dose subacute study conducted in dogs. There were no clinical signs of inflammation at the injection site. Histopathological analysis of the area around the injection site did not reveal any gross abnormalities in any animals. No necrosis or inflammatory cells were observed in the skin surrounding the injection site.

## REFERENCES

1. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Arsenic. ATSDR/TP-92/02. US Department of Health and Human Services. Atlanta, Georgia: US Public Health Service. 2007.
2. Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F et al. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. *Cancer Epidemiol Biomarkers Prev*. 2007;16(6):1270-8.
3. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. *J Clin Oncol*. 2003 Oct 1;21(19):3609-15.
4. Beck LV. Action of adrenal hormones on lethal toxicities of certain organic compounds. *Proc Soc Exp Biol Med*. 1951;78:392-7.
5. Bencko V. Oxygen consumption by mouse liver homogenate during drinking water arsenic exposure. *J Hyg Epidemiol Microbiol Immunol*. 1972;16:42-6.
6. Byron WR, Bierbower GW, Brouwer JB, Hansen WH. Pathologic changes in rats and dogs from two-year feeding of sodium arsenite or sodium arsenate. *Toxicol Appl Pharm*. 1967;10:139-47.
7. Chen GQ, Zhu J, Shi X-G, Ni JH, Zhong HJ, Si GY et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) in the treatment of acute promyelocytic leukemia: As<sub>2</sub>O<sub>3</sub> induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. *Blood*. 1996;88:1052-61.
8. Chen Z, Wang ZY, Chen SJ. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. *Pharmacol Ther*. 1997;76:141-9.
9. Csanaky I, Gregus Z. Effect of phosphate transporter and methylation inhibitor drugs on the disposition of arsenate and arsenite in rats. *Toxicol Sci*. 2001;63(1):29-36.
10. Csanaky I, Nemeti B, Gregus Z. Dose-dependent biotransformation of arsenite in rats – not S-adenosylmethionine depletion impairs arsenic methylation at high dose. *Toxicol*. 2003;183:77-91.
11. Deknadt G, Leonard A, Arany J, Jenar-Du Buissen G, Delavignette E. In vivo studies in male mice on the mutagenic effects of inorganic arsenic. *Mutagenesis*. 1986;1:33-4.
12. Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. *Circulation*. 2004;109:26-9.
13. Eguchi N, Kuroda K, Endo G. Metabolites of arsenic induced tetraploids and mitotic arrest in cultured cells. *Arch Environ Contam Toxicol*. 1997;32:141-145.
14. Ferreira M, Cerejeira MR, Nunes B, de Lourdes, Pereira M. Impairment of mice spermatogenesis by sodium arsenite. *Hum Exp Toxicol*. 2011; 000(00):1-13.
15. Ficker E, Kuryshv YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. *Mol Pharmacol*. 2004;66 (1):33-44.
16. Fielder RJ, Dale EA, Williams SD. Toxicity Review 16. Inorganic Arsenic Compounds. London, England: HMSO Publication Center; 1986:1-95.
17. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. *Blood*. 2008;111(2):556-573.

18. Harrison JWE, Packman EW, Abbott DD. Acute oral toxicity and chemical and physical properties of arsenic trioxides. *AMA Arch Ind Health*. 1958;17:118-23.
19. Hayashi H, Kanisawa M, Yamanaka K, Ito T, Udaka N, Ohji H et al. Dimethylarsinic acid, a main metabolite of inorganic arsenics, has tumorigenicity and progression effects in the pulmonary tumors of A/J mice. *Cancer Lett*. 1998;125:83-88.
20. Heywood R, Sortwell RJ. Arsenic intoxication in the rhesus monkey. *Toxicol Letters*. 1979;3:137-44.
21. Hood RD, Harrison WP. Effects of prenatal arsenite exposure in the hamster. *Bull Environ Contam Toxicol*. 1982;29:671-8.
22. Hood RD, Vedel-Macranders GC. Evaluation of the effect of BAL (2,3-dimercaptopropanol) on arsenite-induced teratogenesis in mice. *Toxicol Appl Pharmacol*. 1984;73:1-7.
23. IARC. Arsenic and arsenic compounds. In: *Some inorganic and organometallic compounds*. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, vol. 2. Lyon, France: International Agency for Research on Cancer; 1972:48-73.
24. IARC. Arsenic and arsenic compounds. In: *Some Metals and Metallic Compounds*. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, vol. 23. Lyon, France: International Agency for Research on Cancer; 1980:39-141.
25. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 100. A Review of Human Carcinogens. Part C: Arsenic, Metals, Fibres and Dusts. France, 2012.
26. IARC. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man*. 1987;7(suppl):100-6.
27. Itoh T, Zhang YF, Murai S, Saito H, Nagahama H, Miyate H et al. The effect of arsenic trioxide on brain monoamine metabolism and locomotor activity of mice. *Toxicol Lett*. 1990;54(2-3): 345-53.
28. Jana K, Jana S, Kumar Samanta P. Effects of chronic exposure to sodium arsenite on hypothalamo-pituitary-testicular activities in adult rats: Possible and estrogenic mode of action. *Reprod Biol Endocrin*. 2006;4:9.
29. Jing Y, Dai J, Chalmers-Redman RME, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen-dependent pathway. *Blood*. 1999;94:2102-11.
30. Kashiwada E, Kuroda K, Endo G. Aneuploidy induced by dimethylarsinic acid in mouse bone marrow cells. *Mutat Res*. 1998;413:33-38.
31. Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K et al. Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCIN mice. *Leukemia*. 2000;14:431-8.
32. Kinoshita A, Wanibuchi H, Morimura K, Wei M, Nakae D, Arai T et al. Carcinogenicity of dimethylarsinic acid in *Ogg1*-deficient mice. *Cancer Sci*. 2007;98(6):803-814.
33. Kobayashi Y, Hirano S. Effects of endogenous hydrogen peroxide and glutathione on the stability of arsenic metabolites in rat bile. *Toxicol Appl Pharmacol*. 2008;232:33-40.
34. Lee HL, Chang LW, Wu JP, Ueng Y-F, Tsai M-H, Hsientang Hsieh DP, et al. Enhancements of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism and carcinogenic risk via NNK/arsenic interaction. *Toxicol Appl Pharmacol*. 2008;227(1):108-14.

35. Lee TC, Oshimura M, Barrett JC. Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. *Carcinogenesis*. 1985;6:1421-6.
36. Lee TC, Tanaka N, Lamb PW, Gilmer TM, Barrett C. Induction of gene amplification by arsenic. *Report. Science*. 1988;241:79-81.
37. Li JH, Rossman TG. Mechanism of comutagenesis of sodium arsenite with n-methyl-n-nitrosurea. *Biological Trace Element Research*. 1989;21:373-81.
38. Life Systems, Inc. Clement International Corporation, United States. Agency for Toxic Substances and Disease Registry. Toxicological profile for arsenic. U.S. Dept. of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry; 1993.
39. Lindgren A, Vahter M, Dencker L. Autoradiographic studies on the distribution of arsenic in mice and hamsters administered <sup>74</sup>As-arsenite or -arsenate. *Acta Pharmacol Toxicol (Copenh)*. 1982;51(3):253-65
40. Lynn S, Lai HT, Gurr JR, Jan KY. Arsenite retards DNA break rejoining by inhibiting DNA ligation. *Mutagenesis*. 1997;12:353-8.
41. Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. *Mutation Research*. 1997;386:263-77.
42. Medina-Díaz IM, Estrada-Muñiz E, Reyes-Hernández OD, Ramírez P, Vega L, Elizondo G. Arsenite and its metabolites, MMA(III) and DMA(III), modify CYP3A4, PXR and RXR alpha expression in the small intestine of CYP3A4 transgenic mice. *Toxicol Appl Pharmacol*. 2009;239(2):162-8.
43. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. *Cancer Res*. 2002;62:3893-903.
44. Monzen H, Griffin RJ, Williams BW, Amano M, Ando S, Hasegawa T. Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor. *Radiation Medicine*. 2004;22:205-11
45. Muto A, Kizaki M, Kawamura C, Matsushita H, Fukuchi Y, Umezawa A et al. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. *Leukemia*. 2001;15:1176-84.
46. National Research Council. Disposition of inorganic arsenic. Arsenic in drinking water. Washington DC, National Academy of Sciences. 1999; 150-76.
47. Oberly TJ, Piper CE, McDonald DS. Mutagenicity of metal salts in the L5178Y mouse lymphoma assay. *J Toxicol Env Health*. 1982;9:367-76.
48. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Natio K et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. *Leukemia*. 2002;16:617-22.
49. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Natio K et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. *Ann Inter Med*. 2000;133(11):881-5.
50. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As<sub>2</sub>O<sub>3</sub> treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PMLRARalpha and PLZF-RARalpha oncoproteins. *Proc Natl Acad Sci USA*. 2000;97:10173-8.
51. Salim EI, Wanibuchi H, Morimura K, Wei M, Mitsuhashi M, Yoshida K et al. Carcinogenicity of dimethylarsinic acid in p53 heterozygous knockout and wild-type C57BL/6J mice. *Carcinogenesis*. 2003;24(2):335-342.

52. Snider TH, Wienthes MG, Joinger RL, Fisher GL. Arsenic distribution in rabbits after Lewisite Administration and Treatment with British Anti-Lewisite (BAL)<sup>1</sup>. *Fund Appl Toxicol.* 1990;14:262-72.
53. Soffritti M, Belpoggi F, Esposti DD, Lambertini L. Results of a Long-Term Carcinogenicity Bioassay on Sprague-Dawley Rats Exposed to Sodium Arsenite Administered in Drinking Water. *Ann N.Y. Acad Sci.* 2006;1076:578-591.
54. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. *N Engl J Med.* 1998;339(19):1341-8.
55. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. *J Clin Oncol.* 2001;19(18):3852-60.
56. Stump DG, Holson JF, Fleeman TL, Nemec MD, Farr CH. Comparative Effects of Single Intraperitoneal or Oral Doses of Sodium Arsenate or Arsenic Trioxide During In Utero Development. *Teratology.* 1999;60:283-291.
57. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. *Blood.* 1992;79:543-53.
58. Tice RR, Yager JW, Andrews P, Crecelius E. Effect of hepatic methyl donor status on urinary excretion and DNA damage in B6C3F1 mice treated with sodium arsenite. *Mutat Res.* 1997;386(3):315-34.
59. Unnikrishnan, D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. *Blood.* 2001; 97:1514-1516.
60. Vahter M. Mechanisms of arsenic biotransformation. *Toxicology* 2002;181-182:211-7.
61. Vahter M, Marafante E. Effects of low dietary intake of methionine, choline or proteins on the biotransformation of arsenite in the rabbit. *Toxicol Lett.* 1987;37(1):41-6.
62. Waalkes MP, Keefer LK, Diwan BA. Induction of Proliferative Lesions of the Uterus, Testes, and Liver in Swiss Mice Given Repeated Injections of Sodium Arsenate: Possible Estrogenic Mode of Action. *Toxicol Appl Pharmacol.* 2000;155:24-35.
63. Waalkes MP, Liu J, Diwan BA. Transplacental arsenic carcinogenesis in mice. *Toxicol Appl Pharmacol.* 2007;222:271-80.
64. Waalkes MP, Liu J, Ward JM, Diwan BA. Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen. *Toxicol Appl Pharmacol.* 2006a;215:295-305.
65. Waalkes MP, Liu J, Ward JM, Powell DA, Diwan BA. Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. *Cancer Res.* 2006b;66:1337-45.
66. Waalkes MP, Ward JM, Diwan BA. Induction of tumours of the liver, lung, ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers. *Carcinogenesis.* 2004;25:133-41.
67. Waalkes MP, Ward JM, Liu J, Diwan BA. Transplacental carcinogenicity of inorganic arsenic in drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumours in mice. *Toxicol Appl Pharmacol.* 2003;186:7-17.
68. Weincke JK, Yager JW. Specificity of arsenite in potentiating cytogenetic damage induced by the DNA crosslinking agent diepoxybutane. *Environmental and Molecular Mutagenesis.* 1992;19:195-200.

69. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. *Blood*. 2001 Jul 15;98(2):266-71.
70. Willhite CC, Fern VH. Prenatal and developmental toxicology of arsenicals. *Adv Exp Med Biol*. 1984;177:205-28.
71. World Health Organization. Summary and recommendations for further research. *Environmental Health 18. Arsenic*. Geneva, World Health Organization. 1981; 13-24.
72. Zhu J, Guo WM, Yao YY, et al. Tissue factors on acute promyelocytic leukemia and endothelial cells are differentially regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. *Leukemia*. 1999;13:1062-70
73. Zuo C, Li P. Pathological observation of toxicity test of intravenously administered arsenic trioxide solution into beagle dogs for 90 days. *Cell Therapeutics Inc*. 1998.



**PART III: CONSUMER INFORMATION**

**PrTRISENOX®**  
**Arsenic trioxide for injection**  
**Ampoule 10 mg/10 mL (1 mg/mL)**  
**Vial 12 mg/6 mL (2 mg/mL)**

This leaflet is part III of a three-part "Product Monograph" published when TRISENOX was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about TRISENOX. Contact your doctor or pharmacist if you have any questions about the drug.

**ABOUT THIS MEDICATION****What the medication is used for:**

TRISENOX is used to treat patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from retinoid and anthracycline chemotherapy. APL is a unique type of myeloid leukemia, a disease in which abnormal white blood cells and abnormal bleeding and bruising occur.

**What it does:**

The active substance in TRISENOX, arsenic trioxide, is a chemical that has been used in medicines for many years, including for the treatment of leukemia. The way it works in this disease is not completely understood. It is thought to prevent the production of deoxyribonucleic acid (DNA), which is necessary for leukemia cells to grow. Arsenic trioxide may induce death of the cancer cells by degrading a fusion protein found in the cancer cells.

**When it should not be used:**

Do not take TRISENOX if:

- you are allergic or hypersensitive to arsenic or any of the nonmedicinal ingredients in TRISENOX.
- you are pregnant or breastfeeding.

**What the medicinal ingredient is:**

Arsenic trioxide.

**What the non-medicinal ingredients are:**

Hydrochloric acid, sodium hydroxide and water for injection.

**What dosage forms it comes in:**

Ampoule:

TRISENOX is available as a sterile and clear concentrated solution that contains 10 mg of arsenic trioxide. TRISENOX is supplied in 10 mL ampoules. Each carton contains 10 single-use glass ampoules.

Vial:

TRISENOX is available as a sterile and clear concentrated solution that contains 12 mg of arsenic trioxide. TRISENOX is supplied in 6 mL vials. Each carton contains 10 single-use glass vials.

## WARNINGS AND PRECAUTIONS

### Serious Warnings and Precautions

- Treatment with TRISENOX may lead to a condition called “APL Differentiation Syndrome” which includes difficulty in breathing, weight gain, coughing, chest pain, fever and may cause death.
- TRISENOX has an effect on the electrical activity of the heart known as prolongation of the QT interval. The prolongation of the QT interval can lead to arrhythmias such as torsade pointes, which may be experienced as dizziness, palpitations and fainting and can result in death.
- Before your first dose of TRISENOX, your doctor will perform a 12-lead electrocardiogram (ECG) and will perform tests to check the amount of potassium, magnesium, calcium and creatinine in your blood.
- While taking TRISENOX, avoid taking drugs that cause a change in the rhythm of your heartbeat or drugs that cause a change in electrolyte levels (potassium, calcium and magnesium).
- TRISENOX should be administered under the supervision of a physician who is experienced in the management of patients with acute leukemia.
- Treatment with Trisenox may cause a condition called Encephalopathy (brain disease) which sometimes may lead to death.

### BEFORE you use TRISENOX® talk to your doctor or pharmacist if:

- you have kidney or liver problems;
- you have any problems with your heart, including irregular heartbeat;
- you plan to become pregnant. TRISENOX may cause harm to the fetus when used by pregnant women. If you are able to become pregnant, you must use effective birth control during treatment with TRISENOX and 3 months after the TRISENOX therapy has stopped.
- you are pregnant or you become pregnant during the treatment with TRISENOX, you must ask your doctor for advice;
- you are breast-feeding. Arsenic will be present in the milk of TRISENOX patients who are breast-feeding. Because of the potential for serious side-effects in nursing infants from TRISENOX, do not breast-feed while on TRISENOX and 3 months after the TRISENOX therapy has stopped.

Men should also use effective contraception during treatment with TRISENOX and for 3 months after TRISENOX therapy has stopped.

## INTERACTIONS WITH THIS MEDICATION

### Drugs that may interact with TRISENOX include:

Various types of medicines which may have unwanted effect on the function of the heart (QT prolongation) such as:

- antiarrhythmics (e.g., quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dronedarone, flecainide, propafenone) - used to treat irregular heart beat
- antipsychotics (e.g., chlorpromazine, pimozide, haloperidol, droperidol, ziprasidone) - used to treat schizophrenia or other psychiatric diseases
- antidepressants (e.g., fluoxetine, citalopram, venlafaxine, amitriptyline, imipramine, maprotiline) - used to treat depression
- opioids (e.g., methadone)
- antibiotics (e.g., erythromycin, clarithromycin, telithromycin, moxifloxacin, levofloxacin, ciprofloxacin) - used to treat infections
- tacrolimus - used to prevent organ rejection

- antimalarials (e.g., quinine, chloroquine) - used to treat malaria
- antifungals (e.g., ketoconazole, fluconazole, voriconazole) - used to treat infections
- domperidone - used to treat gastrointestinal disorders
- dolasetron, ondansetron - used to treat nausea
- vorinostat, vandetanib, sunitinib, nilotinib, lapatinib -used to treat cancer
- salmeterol, formoterol - used to treat asthma

Any medicines that cause imbalance in the electrolytes in your body:

- diuretics (water pills)
- laxatives and enemas
- amphotericin B
- high dose corticosteroids

Anthracyclines – cancer chemotherapy drugs

The above lists of potentially interacting drugs are not comprehensive.

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines even those not prescribed (including any over-the-counter drugs, vitamins, or herbal medicines).

## PROPER USE OF THIS MEDICATION

### Usual dose:

TRISENOX must be injected under the supervision of a physician experienced in the treatment of acute leukemias.

Your doctor will dilute TRISENOX with 100 to 250 mL of glucose 50 mg/mL (5%) injection, or sodium chloride 9 mg/mL (0.9%) injection.

Your doctor will infuse TRISENOX through a tube into a blood vessel over 1-2 hours, but the infusion may last longer if side-effects like flushing and dizziness occur.

Your doctor will give you TRISENOX once every day as a single infusion each day. In your first treatment cycle, you may be treated every day up to 60 days at most, or until your doctor determines that your disease is better. If your disease responds to TRISENOX, you will be given a second treatment cycle of 25 doses, given 5 days per week followed by a 2 day break for 5 weeks. Your doctor will decide exactly how long you must continue on therapy with TRISENOX.

### Overdose:

If you experience symptoms suggestive of acute arsenic toxicity such as convulsions, muscle weakness and confusion, TRISENOX must be stopped immediately and your doctor will treat the arsenic overdose.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

## SIDE EFFECTS AND WHAT TO DO ABOUT THEM

TRISENOX can have side effects, like all medicines, but not everybody gets them. For further information about any of these side effects, ask a doctor or pharmacist.

Tell your doctor or nurse straight away if you notice the following side effects, as these may be signs of a severe condition called “differentiation syndrome”, which can lead to death:

- difficulty in breathing

- coughing
- chest pain
- fever
- weight gain

You might experience encephalopathy (a general term for brain disease) with various symptoms including difficulties to use arms and legs, speech disorders and confusion. The frequency of this side effect is not known.

If you experience any symptom that bothers you or does not go away contact your doctor or seek medical attention as soon as possible.

The following very common side effects (> 10%) have been observed during clinical trials involving patients taking TRISENOX.

- increased heart rate, feeling of your heart pounding
- eye irritation, blurred vision
- nausea, diarrhea, vomiting, stomach pain, constipation, upper stomach pain, indigestion, bleeding in the mouth
- feeling weak or tired
- fever, chills
- swelling, swelling of the limbs
- chest pain
- pain or redness or swelling at the injection site
- inflammation of the sinuses, cold sores, cold-like symptoms, pneumonia
- weight gain
- abnormal breath sounds
- decreased appetite
- pain (joint pain, muscle pain, bone pain, back pain, neck pain, pain in limbs)
- headache
- dizziness
- pins and needles feeling, reduced sense of touch, trembling
- sleeplessness, feeling anxious, depression
- blood in urine
- bleeding from vagina
- cough, shortness of breath, throat pain, nose bleeds, wheezing, crackling sounds in your lungs
- inflammation of the skin, itchiness, bruises, dry skin, redness
- increased sweating
- low blood pressure, flushing, high blood pressure, paleness

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
		Only if severe	In all cases	
<b>Very Common</b>	Difficulty in breathing			√
	Coughing			√
	Chest pain			√
	Fever			√
	Weight gain			√
	Irregular heartbeat, fainting, loss of consciousness (QT prolongation)		√	
	Diarrhoea	√		
	Nausea, Vomiting	√		
	Fast heartbeat, pounding sensation		√	
	Fatigue (weariness) Weakness	√		
	Numbness or tingling in your feet or hands	√		
	Unusual bruising or bleeding		√	

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
		Only if severe	In all cases	
	Any sign of high blood sugar : extreme thirst, frequent urination, extreme hunger, weakness or blurred vision	√		
	Pain		√	
<b>Uncommon</b>	Brain disease called Encephalopathy			√

*This is not a complete list of side effects. For any unexpected effects while taking TRISENOX®, contact your doctor or pharmacist.*

## HOW TO STORE IT

Keep out of reach and sight of children.

Do not use after expiry date which is stated on the ampoule or vial label.

Store at controlled room temperature (15 to 30°C). Do not freeze.

Do not use TRISENOX if you notice foreign particulate matter or if the solution is discoloured.

### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

## MORE INFORMATION

For questions or concerns and to find the full product monograph prepared for healthcare professionals, go to <http://www.tevacanadainnovation.ca> or contact the sponsor, Teva Canada Innovation at 1-833-662-5644.

This leaflet was prepared by Teva Canada Innovation.

Last revised: October 16, 2020